Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Fish and Richardson
Fuji
McKinsey
Express Scripts
Cantor Fitzgerald
Moodys
Dow
Deloitte
US Army

Generated: February 24, 2018

DrugPatentWatch Database Preview

HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% Drug Profile

« Back to Dashboard

When do Heparin Sodium 12,500 Units In Dextrose 5% patents expire, and when can generic versions of Heparin Sodium 12,500 Units In Dextrose 5% launch?

Heparin Sodium 12,500 Units In Dextrose 5% is a drug marketed by Hospira and is included in two NDAs.

The generic ingredient in HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% is heparin sodium. There are seventy-seven drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the heparin sodium profile page.
Summary for HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%
Drug patent expirations by year for HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%

US Patents and Regulatory Information for HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hospira HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% heparin sodium INJECTABLE;INJECTION 018911-007 Jan 30, 1985 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Hospira HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER heparin sodium INJECTABLE;INJECTION 019339-001 Mar 27, 1985 RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Julphar
QuintilesIMS
Medtronic
Covington
Citi
Daiichi Sankyo
Chubb
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot